Cell and Gene Therapy CMO and CDMO Facilities
Searchable and sortable database of 197 Cell and Gene Therapy CMOs / CDMOs worldwide as of June 2021, including 147 companies and 50 academic or government facilities.
This is a global database of facilities that provide (mostly or exclusively) services as contract manufacturing organizations (CMO) and/or contract development and manufacturing organizations (CDMO) for the cell and gene therapy industry worldwide.
Included: Manufacturers of therapeutic cell products (unmodified or gene-modified), iPS cell lines for therapeutic products, viral vectors and DNA plasmids for cell and gene therapy industry.
Excluded: Contract research organizations (CROs) not performing manufacture of the therapeutic product, vendors of supplies (reagents, devices, etc.)
For each company:
- Facility name
- Link to facility website if available
- Country of origin
- CMO/CDMO service expertise
- Mergers & Acquisitions, Notes
- The excel file has separate lists for CMO/CDMO that are Industry versus Academic/ Government facilities.
Geographically, our January 2020 database held 69 facilities operating in North America (40%), 69 in Europe (40%), and 35 (20%) in Asia. We had 173 locations for the 161 facilities in our Jan. 2020 database because some of the companies have laboratories in more than one country.
Our last release in Sept. 2020 held 188 CMO/CDMO, including 140 companies and 48 academic or government facilities. Since then, we have added 15 organizations (13 industry companies and 2 academic/government) and removed 6 organizations due to acquisitions (Aldevron, Cognate Bioservices, DelphiGenetics, Oxgene, Vigene, Yposkesi). We also recorded the following changes: 7 company name/web-site, 2 country of origin, 3 services, 5 mergers and acquisitions.
Our previous release in March 2020 held 174 CMO/CDMO. Between then and the next release we added 16 organizations (14 industry companies and 2 academic/government) and removed 2 organizations due to acquisitions.Public samples:
|SAMPLE Cell and Gene Therapy CMO and CDMO Facilities||11.3 KB|